Observational Study

. 2021 Jul;20(4):566-577.

doi: 10.1016/j.jcf.2021.03.017. Epub 2021 Apr 18.

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Lutz Naehrlich¹, Annalisa Orenti², Fiona Dunlevy³, Irena Kasmi⁴, Satenik Harutyunyan⁵, Andreas Pfleger⁶, Svetlana Keegan⁷, Géraldine Daneau⁸, Guergana Petrova⁹, Duška Tješić-Drinković¹⁰, Panayiotis Yiallouros¹¹, Alena Bilkova¹², Hanne Vebert Olesen¹³, Pierre-Régis Burgel¹⁴, Tsitsino Parulava¹⁵, Filia Diamantea¹⁶, Andrea Párniczky¹⁷, Edward F McKone¹⁸, Meir Mei-Zahav¹⁹, Marco Salvatore²⁰, Carla Colombo²¹, Elina Aleksejeva²², Kestutis Malakauskas²³, Marc Schlesser²⁴, Stojka Fustik²⁵, Oxana Turcu²⁶, Domenique Zomer-van Ommen²⁷, Anita Senstad Wathne²⁸, Łukasz Woźniacki²⁹, Luísa Pereira³⁰, Liviu Pop³¹, Nataliya Kashirskaya³², Milan Rodić³³, Hana Kayserova³⁴, Uro Krivecs³⁵, Pedro Mondejar-Lopez³⁶, Isabelle de Monestrol³⁷, Deniz Dogru³⁸, Halyna Makukh³⁹, Rebecca Cosgriff⁴⁰, Silke van Koningsbruggen-Rietschel⁴¹, Andreas Jung⁴²; European Cystic Fibrosis COVID project group

Collaborators, Affiliations

Collaborators

European Cystic Fibrosis COVID project group:
Vladimir Bobrovnichy⁷, Ivan Bambir¹⁰, Andrea Dugac Vukic¹⁰, Pavel Drevinek⁴³, Milan Macek Jr⁴⁴, Harriet Corvol⁴⁵, Lydie Lemonnier-Videau⁴⁶, Elpis Hatziagorou⁴⁷, Godfrey Fletcher⁴⁸, Rita Padoan⁴⁹, Vincent Gulmans²⁷, Egil Bakkeheim²⁸, Elena Kondratyeva⁵⁰, Elena Amelina²⁸, Elena Zhekaite⁵¹, Olga Simonova⁵², Maria Dolores Pastor-Vivero⁵³, Anders Lindblad⁵⁴, Yasemin Gökdemir⁵⁵, Sevgi Pekcan⁵⁶, Keith Brownlee⁴⁰, Elliott McClenaghan⁴⁰, Siobhán Carr⁸, Elise Lammertyn⁵⁷, Anna Zolin², Alice Fox⁵⁸, Marko Krasnyk⁵⁸, Jacqui Van Rens⁵⁸

Affiliations

¹ Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany.
² Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.
³ European Cystic Fibrosis Society, Karup, Denmark.
⁴ "Mother Thereza" Hospital Center, Department of Paediatrics, Tirana, Albania.
⁵ Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.
⁶ Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria.
⁷ Belarusian Republic Children's Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children's Clinical Hospital, Minsk, Belarus.
⁸ Sciensano, Epidemiology and public health, Health services research, Brussels, Belgium.
⁹ Alexandrovska University Hospital, Pediatric Clinic, Sofia, Bulgaria.
¹⁰ University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia.
¹¹ Medical School, University of Cyprus, Nicosia, Cyprus.
¹² Cystic Fibrosis Registry of the Czech Republic, Prague, Czech Republic.
¹³ Department of Pediatrics and Adolescent Medicine, Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark.
¹⁴ Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Cochin, INSERM U1016, Paris, France.
¹⁵ I. Tsitsishvili Children's Clinic, CF Centre, Tblisi, Georgia.
¹⁶ Sismanoglio General Hospital of Attica, Adult Cystic Fibrosis Unit, Athens, Greece.
¹⁷ Heim Pál National Pediatric Institute, Budapest, Hungary; Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary.
¹⁸ St. Vincent's University Hospital & University College Dublin School of Medicine, Dublin, Ireland.
¹⁹ Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁰ Undiagnosed Rare Diseases Interdepartmental Unit, National Center Rare Diseases, Istituto Superiore di Sanità, Rome, Italy.
²¹ Cystic Fibrosis Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.
²² Department of Pneumology, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia.
²³ Adult Cystic Fibrosis center, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
²⁴ Department of Pulmonology, Hôpital Robert Schuman, Luxembourg, Luxembourg.
²⁵ Centre for Cystic Fibrosis, University Children's Hospital, Skopje, North Macedonia.
²⁶ Ambulatory Cystic Fibrosis and Other Rare Diseases Center, Institute for Maternal and Child Healthcare, State University of Medicine and Pharmacy "Nicolae Testemitanu", Department of Pediatrics, Chisinau, Republic of Moldova.
²⁷ Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands.
²⁸ Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway.
²⁹ Dziekanow Paediatric Hospital, Cystic Fibrosis Centre, Institute of Mother and Child, Warsaw, Poland.
³⁰ Centre for Cystic Fibrosis, Hospital de Santa Maria, Lisbon, Portugal.
³¹ Victor Babes University of Medicine and Pharmacy Timisoara, National Cystic Fibrosis Centre Timisoara, Romania.
³² Laboratory of genetic epidemiology, "Research Centre for Medical Genetics", Moscow, Russian Federation.
³³ National Centre for Cystic Fibrosis, Mother and Child Health Institute of Serbia "Dr Vukan Čupić", Belgrade, Serbia.
³⁴ Cystic Fibrosis Centre, University Hospital of Bratislava, Bratislava, Slovakia.
³⁵ Department of Paediatric Pulmonology, University Children's Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia.
³⁶ Pediatric Pulmonology and Cystic Fibrosis Unit, Virgen de la Arrixaca Clinic University Hospital, Murcia, Spain.
³⁷ Stockholm CF centre, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
³⁸ Cystic Fibrosis Registry of Turkey, Ankara, Turkey.
³⁹ Institute of Hereditary Pathology Ukrainian National Academy of Medical Sciences, Lviv, Ukraine.
⁴⁰ Cystic Fibrosis Trust, London, UK.
⁴¹ CF-Center, University of Cologne, Faculty of Medicine, Cologne, Germany.
⁴² Paediatric Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.
⁴³ Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁴⁴ Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁴⁵ Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Pediatric Pulmonology Department and Cystic Fibrosis Center, Paris, France.
⁴⁶ Vaincre la Mucoviscidose, Paris, France.
⁴⁷ Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴⁸ The Cystic Fibrosis Registry of Ireland, Dublin, Ireland.
⁴⁹ Cystic Fibrosis Regional Support Centre, Department of Paediatrics, University of Brescia, Brescia, Italy.
⁵⁰ Clinical research department of cystic fibrosis "Research Centre for Medical Genetics", Moscow, Russian Federation.
⁵¹ Cystic Fibrosis Department, Pulmonology Research Institute of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation.
⁵² Center for rare disease National Medical Research Center for Children's Health, Moscow, Russia; Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Moscow, Russian Federation.
⁵³ Pediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain.
⁵⁴ Gothenburg CF Centre, Queen Silvia Children's Hospital, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
⁵⁵ Division of Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.
⁵⁶ Division of Pediatric Pulmonolgy, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
⁵⁷ Cystic Fibrosis Europe, Brussels; Association Muco A.S.B.L. - Mucovereniging V.Z.W., Brussels, Belgium.
⁵⁸ European Cystic Fibrosis Society Patient Registry, Karup, Denmark.

PMID: 34016559
PMCID: PMC8053246
DOI: 10.1016/j.jcf.2021.03.017

Observational Study

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Lutz Naehrlich et al. J Cyst Fibros. 2021 Jul.

. 2021 Jul;20(4):566-577.

doi: 10.1016/j.jcf.2021.03.017. Epub 2021 Apr 18.

Authors

Collaborators

European Cystic Fibrosis COVID project group:
Vladimir Bobrovnichy⁷, Ivan Bambir¹⁰, Andrea Dugac Vukic¹⁰, Pavel Drevinek⁴³, Milan Macek Jr⁴⁴, Harriet Corvol⁴⁵, Lydie Lemonnier-Videau⁴⁶, Elpis Hatziagorou⁴⁷, Godfrey Fletcher⁴⁸, Rita Padoan⁴⁹, Vincent Gulmans²⁷, Egil Bakkeheim²⁸, Elena Kondratyeva⁵⁰, Elena Amelina²⁸, Elena Zhekaite⁵¹, Olga Simonova⁵², Maria Dolores Pastor-Vivero⁵³, Anders Lindblad⁵⁴, Yasemin Gökdemir⁵⁵, Sevgi Pekcan⁵⁶, Keith Brownlee⁴⁰, Elliott McClenaghan⁴⁰, Siobhán Carr⁸, Elise Lammertyn⁵⁷, Anna Zolin², Alice Fox⁵⁸, Marko Krasnyk⁵⁸, Jacqui Van Rens⁵⁸

Affiliations

¹ Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany.
² Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy.
³ European Cystic Fibrosis Society, Karup, Denmark.
⁴ "Mother Thereza" Hospital Center, Department of Paediatrics, Tirana, Albania.
⁵ Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.
⁶ Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria.
⁷ Belarusian Republic Children's Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children's Clinical Hospital, Minsk, Belarus.
⁸ Sciensano, Epidemiology and public health, Health services research, Brussels, Belgium.
⁹ Alexandrovska University Hospital, Pediatric Clinic, Sofia, Bulgaria.
¹⁰ University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia.
¹¹ Medical School, University of Cyprus, Nicosia, Cyprus.
¹² Cystic Fibrosis Registry of the Czech Republic, Prague, Czech Republic.
¹³ Department of Pediatrics and Adolescent Medicine, Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark.
¹⁴ Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Cochin, INSERM U1016, Paris, France.
¹⁵ I. Tsitsishvili Children's Clinic, CF Centre, Tblisi, Georgia.
¹⁶ Sismanoglio General Hospital of Attica, Adult Cystic Fibrosis Unit, Athens, Greece.
¹⁷ Heim Pál National Pediatric Institute, Budapest, Hungary; Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary.
¹⁸ St. Vincent's University Hospital & University College Dublin School of Medicine, Dublin, Ireland.
¹⁹ Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁰ Undiagnosed Rare Diseases Interdepartmental Unit, National Center Rare Diseases, Istituto Superiore di Sanità, Rome, Italy.
²¹ Cystic Fibrosis Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy.
²² Department of Pneumology, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia.
²³ Adult Cystic Fibrosis center, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
²⁴ Department of Pulmonology, Hôpital Robert Schuman, Luxembourg, Luxembourg.
²⁵ Centre for Cystic Fibrosis, University Children's Hospital, Skopje, North Macedonia.
²⁶ Ambulatory Cystic Fibrosis and Other Rare Diseases Center, Institute for Maternal and Child Healthcare, State University of Medicine and Pharmacy "Nicolae Testemitanu", Department of Pediatrics, Chisinau, Republic of Moldova.
²⁷ Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands.
²⁸ Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway.
²⁹ Dziekanow Paediatric Hospital, Cystic Fibrosis Centre, Institute of Mother and Child, Warsaw, Poland.
³⁰ Centre for Cystic Fibrosis, Hospital de Santa Maria, Lisbon, Portugal.
³¹ Victor Babes University of Medicine and Pharmacy Timisoara, National Cystic Fibrosis Centre Timisoara, Romania.
³² Laboratory of genetic epidemiology, "Research Centre for Medical Genetics", Moscow, Russian Federation.
³³ National Centre for Cystic Fibrosis, Mother and Child Health Institute of Serbia "Dr Vukan Čupić", Belgrade, Serbia.
³⁴ Cystic Fibrosis Centre, University Hospital of Bratislava, Bratislava, Slovakia.
³⁵ Department of Paediatric Pulmonology, University Children's Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia.
³⁶ Pediatric Pulmonology and Cystic Fibrosis Unit, Virgen de la Arrixaca Clinic University Hospital, Murcia, Spain.
³⁷ Stockholm CF centre, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
³⁸ Cystic Fibrosis Registry of Turkey, Ankara, Turkey.
³⁹ Institute of Hereditary Pathology Ukrainian National Academy of Medical Sciences, Lviv, Ukraine.
⁴⁰ Cystic Fibrosis Trust, London, UK.
⁴¹ CF-Center, University of Cologne, Faculty of Medicine, Cologne, Germany.
⁴² Paediatric Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.
⁴³ Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁴⁴ Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
⁴⁵ Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Pediatric Pulmonology Department and Cystic Fibrosis Center, Paris, France.
⁴⁶ Vaincre la Mucoviscidose, Paris, France.
⁴⁷ Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴⁸ The Cystic Fibrosis Registry of Ireland, Dublin, Ireland.
⁴⁹ Cystic Fibrosis Regional Support Centre, Department of Paediatrics, University of Brescia, Brescia, Italy.
⁵⁰ Clinical research department of cystic fibrosis "Research Centre for Medical Genetics", Moscow, Russian Federation.
⁵¹ Cystic Fibrosis Department, Pulmonology Research Institute of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation.
⁵² Center for rare disease National Medical Research Center for Children's Health, Moscow, Russia; Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Moscow, Russian Federation.
⁵³ Pediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain.
⁵⁴ Gothenburg CF Centre, Queen Silvia Children's Hospital, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
⁵⁵ Division of Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.
⁵⁶ Division of Pediatric Pulmonolgy, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
⁵⁷ Cystic Fibrosis Europe, Brussels; Association Muco A.S.B.L. - Mucovereniging V.Z.W., Brussels, Belgium.
⁵⁸ European Cystic Fibrosis Society Patient Registry, Karup, Denmark.

PMID: 34016559
PMCID: PMC8053246
DOI: 10.1016/j.jcf.2021.03.017

Abstract

Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF).

Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection.

Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133).

Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

Keywords: Covid-19; Cystic fibrosis; Epidemiology; Europe; Incidence; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals and Boehringer Ingelheim; Dr. Orenti has nothing to disclose; Dr. Dunlevy reports institutional grants from Chiesi, during the conduct of the study; Dr. Kasmi has nothing to disclose; Dr. Harutyunyan has nothing to disclose; Dr. Pfleger has nothing to disclose; Dr. Bobrovnichy has nothing to disclose;Dr. Keegan has nothing to disclose; Dr. Daneau has nothing to disclose; Dr. Petrova has nothing to disclose; Dr. Bambir has nothing to disclose; Dr. Vukić Dugac has nothing to disclose; Dr. Tješić-Drinković has nothing to disclose; Dr. Yiallouros has nothing to disclose; Dr. Drevinek reports personal fees from Vertex Pharmaceuticals, outside the submitted work; Prof. Milan Macek reports grants from Vertex Pharmaceuticals, outside the submitted workr r; Mrs. Bilkova has nothing to disclose; Dr. Olesen has nothing to disclose; Dr. Burgel reports personal fees from Astra-Zeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Insmed, personal fees from Novartis, personal fees from Pfizer, grants and personal fees from Vertex, personal fees from Zambon, outside the submitted work; Dr. Corvol has nothing to disclose; Ms. Lemmonier has nothing to disclose; Dr. Parulava has nothing to disclose; Dr. Hatziagorou has nothing to disclose; Dr. Diamantea has nothing to disclose; Dr. Párniczky has nothing to disclose; G. Fletcher has nothing to disclose; Prof. McKone reports travel support from A Menarini, speaker fees from Roche Pharmaceuticals, consultancy fees from Insmed, consultancy fees from Janssen Pharmaceuticals, grants to institution and consultancy fees from Vertex, outside the submitted work; Dr. Mei-Zahav has nothing to disclose; Dr. Padoan has nothing to disclose; Dr. Salvatore has nothing to disclose; Dr. Colombo has nothing to disclose; Dr. Aleksejeva has nothing to disclose; Dr. Malakauskas has nothing to disclose; Dr. Schlesser has nothing to disclose; Dr. Fustik has nothing to disclose; Dr. Turcu has nothing to disclose; V. Gulmans has nothing to disclose; D. Zomer-van Ommen has nothing to disclose; Dr. Wathne has nothing to disclose; Dr. Bakkeheim has nothing to disclose; Dr. Wozniacki has nothing to disclose; Dr. Pereira has nothing to disclose; Dr. Pop has nothing to disclose; Dr. Kondratyeva has nothing to disclose; Dr. Amelina has nothing to disclose; Dr. Zhekaite has nothing to disclose; Dr. O. Simonova has nothing to disclose; Dr. Kashirskaya has nothing to disclose; Dr. Rodic has nothing to disclose; Dr. Kayserova has nothing to disclose; Dr. Krivec has nothing to disclose; Dr. Mondejar-Lopez has nothing to disclose; Dr. Pastor-Vivero has nothing to disclose; Dr. de Monestrol reports grants from Vertex, outside the submitted work; Dr. Lindblad has nothing to disclose; Dr. Dogru has nothing to disclose; Dr. Gokdemir has nothing to disclose; Dr. Pekcan has nothing to disclose; Dr. Makukh has nothing to disclose; Dr. Brownlee has nothing to disclose; Ms. Cosgriff has nothing to disclose; Mr. McClenaghan has nothing to disclose; Dr. Carr reports personal fees from Chiesi Pharmaceuticals, personal fees and non-financial support from Vertex, personal fees from Zambon, personal fees from Insmed, outside the submitted work; Dr. Lammertyn has nothing to disclose; Dr. Zolin has nothing to disclose; Ms.. Fox reports grants from ECFS, during the conduct of the study; Mr Krasnyk has nothing to disclose; Mrs. Van Rens has nothing to disclose; Dr. van Koningsbruggen-Rietschel reports grants and personal fees from Algipharma (HORIZON2020), personal fees from Deutsches Zentrum für Infektionsforschung, personal fees from Antabio, personal fees from Proteostasis, personal fees from Roche, personal fees from Vertex, outside the submitted work; Dr. Jung reports grants from Chiesi Pharmaceuticals, during the conduct of the study.

Figures

**Fig. 1**
Flow chart on SARS-CoV-2 data collection. 1 Albania, Armenia, Austria, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Georgia, Hungary, Israel, Latvia, Lithuania, Luxembourg, Republic of Moldova, North Macedonia, Portugal, Romania, Serbia, Slovak Republic, Slovenia, Ukraine 2 Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom

**Fig. 2**
Incidence of SARS-CoV-2 infection up to 30 June 2020 in people with cystic fibrosis and in the general population by country. *Abbreviations*: CI=confidence interval, SARS-CoV-2=Severe Acute Respiratory Syndrome Coronavirus 2 Notes: All cases of SARS-CoV-2 in pwCF and the general population were PCR-confirmed. Incidence was calculated as (SARS-CoV-2 cases/number of people in the population)*1000. CF population size was from the 2018 ECFSPR report.

**Fig. 3**
Incidence and rates of hospitalization and intensive care admission by age group and transplant status in people with cystic fibrosis compared to the general population. Notes: Confidence intervals shown as grey shaded area. People with CF aged ≥50 years were grouped together due to low numbers. The 24 countries included in age-banded analysis of incidence in people with CF and the general population were: Austria, Belgium, Croatia, Czech Republic, Cyprus, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden. The 30 countries included in age-banded analysis of hospital and intensive care admission in people with CF and the general population were the 24 countries above plus Bulgaria, Estonia, Finland, Iceland, Malta, United Kingdom.

See this image and copyright information in PMC

References

1. Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One. 2020;15 doi: 10.1371/journal.pone.0243191. - DOI - PMC - PubMed
1. Kiedrowski MR, Bomberger JM. Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract. Front Immunol. 2018;9:3067. doi: 10.3389/fimmu.2018.03067. - DOI - PMC - PubMed
1. Viviani L, Assael BM, Kerem E, group EHNs. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibros. 2011;10:370–376. doi: 10.1016/j.jcf.2011.06.004. - DOI - PubMed
1. Pinar Senkalfa B, Sismanlar Eyuboglu T, Aslan AT, Ramasli Gursoy T, Soysal AS, Yapar D. Effect of the COVID-19 pandemic on anxiety among children with cystic fibrosis and their mothers. Pediatr Pulmonol. 2020;55:2128–2134. doi: 10.1002/ppul.24900. - DOI - PMC - PubMed
1. Corvol H, de Miranda S, Lemonnier L, Kemgang A, Reynaud Gaubert M, Chiron R. First Wave of COVID-19 in French Patients with Cystic Fibrosis. J Clin Med. 2020;9:3624. doi: 10.3390/jcm9113624. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Collaborators

Affiliations

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous